Literature DB >> 32534790

Advanced Prostate Cancer: Treatment Advances and Future Directions.

Umang Swami1, Taylor R McFarland1, Roberto Nussenzveig1, Neeraj Agarwal2.   

Abstract

Prostate cancer affects one in every nine men in the USA and is the second leading cause of cancer-related death. The treatment landscape of advanced prostate cancer is changing rapidly. Multiple agents including abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, radium-223, and sipuleucel-T have been approved for advanced prostate cancer. Appropriate drug selection remains crucial in this evolving landscape to derive maximum benefit for the patients. We summarize clinical trials leading to recent drug approvals and discuss optimal treatment selection. We also review recent advances in genomics including its evolving role in prognosis, in elucidating mechanisms of treatment resistance, and in guiding treatment decisions.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  abiraterone; apalutamide; cabazitaxel; darolutamide; docetaxel; enzalutamide; metastatic prostate cancer

Year:  2020        PMID： 32534790     DOI： 10.1016/j.trecan.2020.04.010

Source DB:  PubMed          Journal:  Trends Cancer        ISSN： 2405-8025


  22 in total

1.  Inhibiting the P2X4 Receptor Suppresses Prostate Cancer Growth In Vitro and In Vivo, Suggesting a Potential Clinical Target.

Authors:  Jiepei He; Yuhan Zhou; Hector M Arredondo Carrera; Alexandria Sprules; Ramona Neagu; Sayyed Amin Zarkesh; Colby Eaton; Jian Luo; Alison Gartland; Ning Wang
Journal:  Cells       Date:  2020-11-20       Impact factor: 6.600

Review 2.  Dual contribution of the mTOR pathway and of the metabolism of amino acids in prostate cancer.

Authors:  Alejandro Schcolnik-Cabrera; Daniel Juárez-López
Journal:  Cell Oncol (Dordr)       Date:  2022-08-29       Impact factor: 7.051

3.  Effects of substrate stiffness on the viscoelasticity and migration of prostate cancer cells examined by atomic force microscopy.

Authors:  Xiaoqiong Tang; Yan Zhang; Jiangbing Mao; Yuhua Wang; Zhenghong Zhang; Zhengchao Wang; Hongqin Yang
Journal:  Beilstein J Nanotechnol       Date:  2022-06-28       Impact factor: 3.272

Review 4.  Liquid Biopsy Based Circulating Biomarkers in Metastatic Prostate Cancer.

Authors:  Eshwari Dathathri; Khrystany T Isebia; Fikri Abali; Martijn P Lolkema; John W M Martens; Leon W M M Terstappen; Ruchi Bansal
Journal:  Front Oncol       Date:  2022-05-20       Impact factor: 5.738

5.  Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).

Authors:  Neeraj Agarwal; Catherine M Tangen; Maha H A Hussain; Shilpa Gupta; Melissa Plets; Primo N Lara; Andrea L Harzstark; Przemyslaw W Twardowski; Channing J Paller; Dylan Zylla; Matthew R Zibelman; Ellis Levine; Bruce J Roth; Amir Goldkorn; Daniel A Vaena; Manish Kohli; Tony Crispino; Nicholas J Vogelzang; Ian M Thompson; David I Quinn
Journal:  J Clin Oncol       Date:  2022-04-21       Impact factor: 50.717

6.  FOXA1 promotes prostate cancer angiogenesis by inducing multiple pro-angiogenic factors expression.

Authors:  Yiming Su; Yu Zhang; Jing Zhao; Wenhao Zhou; Wenhao Wang; Bangmin Han; Xiaohai Wang
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-14       Impact factor: 4.553

7.  Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer.

Authors:  Lingfan Xu; Bing Zhao; William Butler; Huan Xu; Nan Song; Xufeng Chen; J Spencer Hauck; Xia Gao; Hong Zhang; Jeff Groth; Qing Yang; Yue Zhao; David Moon; Daniel George; Yinglu Zhou; Yiping He; Jiaoti Huang
Journal:  Oncogene       Date:  2022-01-20       Impact factor: 9.867

8.  Diagnostic value of integrated 18F-PSMA-1007 PET/MRI compared with that of biparametric MRI for the detection of prostate cancer.

Authors:  Yuping Zeng; Xiaoming Leng; Hengbin Liao; Guihua Jiang; Ping Chen
Journal:  Prostate Int       Date:  2022-03-28

9.  Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance.

Authors:  Deep Pandya; Myra Shah; Fuat Kaplan; Candice Martino; Gillian Levy; Mia Kazanjian; Stephen Batter; John Martignetti; Richard C Frank
Journal:  Cold Spring Harb Mol Case Stud       Date:  2021-02-19

Review 10.  Immune Checkpoint Inhibitors in Prostate Cancer.

Authors:  Shobi Venkatachalam; Taylor R McFarland; Neeraj Agarwal; Umang Swami
Journal:  Cancers (Basel)       Date:  2021-05-02       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.